BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genovis Release: Unique Enzymes Improve Mass Spectrometric Analysis of IgG


6/30/2010 10:57:56 AM

Genovis launches a new kit for mass spectrometry preparation of IgG - Mass Spec Kit - that contains both the FabRICATOR® ( recombinant IdeS) and the IgGZERO™ (recombinant EndoS) enzymes. Using this kit makes it possible to perform both deglycosylation and fragmentation of IgG. The kit processes 1 mg IgG in one hour and the sample can be analyzed directly without further purification. By combining IgGZERO™ with FabRICATOR®, individual fragments of IgG can be studied in more detail with higher accuracy. In addition, the amino acid sequencing for quality control of monoclonal antibodies is facilitated. These unique enzymes have potential to reduce time and cost of quality control during screening, preparation and production of monoclonal antibodies.

When performing mass spectrometry of large proteins, such as IgG molecules, there is often a need to remove the glycans because of poor quality of the data otherwise obtained. Additionally, fragmentation of IgG can visualize individual parts of IgG and allow for studies in more detail. The obvious solution is then to remove the glycans attached to a Asp297 on the Fc part of IgG molecules and we have evaluated a novel endoglycosidase, IgGZERO™, that selectively deglycosylates IgG molecules, for analysis in mass spectrometric applications. Due to its high specificity and activity, complete deglycosylation of native IgG can be done in less than 30 minutes. Deglycosylation followed by fragmentation with FabRICATOR®, which is very specific and effective, generates F(ab’)2 and Fc fragment in less than 30 minutes. This reduces time of preparation significantly and dramatically increase the quality of data obtained when IgG is analyzed by mass spectrometry.

Effect of deglycosylating IgG Fc:

Mass spectrometry of Fc-fragments from human polyclonal IgG purifed from plasma. (A) 1 mg of IgG was incubated with 1000 U of FabRICATOR® for 30 minutes and analyzed by mass spectrometry. (B) 1 mg of human IgG was incubated with 1000 Units of FabRICATOR® for 30 minutes followed by incubation with 1000 Units of IgGZERO™ for 45 minutes and finally analyzed by mass spectrometry. Utilization of RPC18 LC-ESI-MS generated a well-defined protein envelope with a deconvoluted mass of 24137 Da corresponding to the deglycosylated IgG1 heavy chain cleaved at position Gly236.

Homogeneity of F(ab’)2 fragments Pepsin vs FabRICATOR:

Mass spectrometry (LS/MS) of F(ab’)2-fragments from humanized monoclonal IgG (Hercptin?). (A) 1 mg of IgG was digested using Pepsin (Sigma) for 2 hours pH 3.5. F(ab’)2 fragments was isolated by size exclusion chromatography before analyzis by mass spectrometry. (B) 1 mg of IgG was digested using FabRICATOR® for 30 minutes and F(ab’)2 fragments was isolated using size exclusion chromatography before analyzis by mass spectrometry. FabRICATOR® has one unique cleavage site and generates identical fragments, whereas pepsin generates several different fragments due to multiple cleavage sites resulting in a heterogeneous mixture of fragments.

Please contact Fredrik Olsson for additional information. Fredrik Olsson Phone: + 46 46 101233 Fredrik.Olsson@genovis.com www.genovis.com



Read at BioSpace.com

Genovis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES